Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | Global President TAVR & Surg | August 18, 2025 | August 18, 2025 |
| PROCEPT BioRobotics CorpPRCT · Entity 4831 | Director · President, CEO | August 07, 2026 | August 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date August 18, 2025 · Filed August 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 206,900.3913 |
Ending reported balance
After 2025-08-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-08-18 · Exercise / conversion · Acquired 8,950 · Balance 215,850.3913 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. Row 2 · 2025-08-18 · Sale · Disposed 8,950 · Balance 206,900.3913 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F2: This transaction was executed in multiple trades at prices ranging from $77.68 to $78.43. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| Employee Stock Option (Right to Acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $59.26 · Expires 2026-05-07 | Direct | 35,800 |
Reported balance
After 2025-08-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-08-18 · Exercise / conversion · Disposed 8,950 · Balance 35,800 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 148.1703 |
Reported balance
Holding disclosure · report date 2025-08-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 148.1703 |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $77.68 to $78.43. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
PROCEPT BioRobotics Corp
Report date August 07, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectThe Larry Wood Trust | 23,900 |
Reported balance
After 2026-08-07 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-07 · Purchase · Acquired 23,900 · Balance 23,900 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.67 to $21.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 314,203 |
Reported balance
Holding disclosure · report date 2026-08-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 314,203 F2: Includes 825 shares acquired on May 14, 2026, under the Issuer's 2021 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.67 to $21.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2: Includes 825 shares acquired on May 14, 2026, under the Issuer's 2021 Employee Stock Purchase Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2023 Filed Sep 15, 2023 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 8,660 | $45.28 | $392,096.22 |
DisclosureSEC source: 0001225208-23-008936 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 222,453.7137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2023. Read SEC document |
| August 14, 2023 Filed Aug 14, 2023 22:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,421 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-23-008219 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,638 Underlying: Common Stock · 6,421 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2023 Filed Aug 14, 2023 22:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,421 | $79.30 | $509,185.30 |
DisclosureSEC source: 0001225208-23-008219 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,793.7137 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2023. Read SEC document |
| August 14, 2023 Filed Aug 14, 2023 22:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,421 | $45.28 | $290,721.69 |
DisclosureSEC source: 0001225208-23-008219 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 220,214.7137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2023. Read SEC document |
| July 14, 2023 Filed Jul 14, 2023 21:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 8,660 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-23-007511 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,059 Underlying: Common Stock · 8,660 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 14, 2023 Filed Jul 14, 2023 21:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,660 | $92.94 | $804,843.08 |
DisclosureSEC source: 0001225208-23-007511 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,793.7137 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $92.68 to $93.24 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 14, 2023 Filed Jul 14, 2023 21:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 8,660 | $45.28 | $392,096.22 |
DisclosureSEC source: 0001225208-23-007511 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 222,453.7137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2023. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 20:46 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 8,660 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-23-006823 · doc4.xml · derivative · entry 5 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,719 Underlying: Common Stock · 8,660 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 20:46 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,810 | $89.87 | $522,152.25 |
DisclosureSEC source: 0001225208-23-006823 · doc4.xml · nonDerivative · entry 3 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,793.7137 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $89.47 to $90.46 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 20:46 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,850 | $90.71 | $258,528.35 |
DisclosureSEC source: 0001225208-23-006823 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 219,603.7137 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $90.49 to $90.97 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 20:46 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 8,660 | $45.28 | $392,096.22 |
DisclosureSEC source: 0001225208-23-006823 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 222,453.7137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2023. Read SEC document |
| May 24, 2023 Filed May 24, 2023 23:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,421 | $0.00 Strike: $45.28 | $0.00 |
DisclosureSEC source: 0001225208-23-006208 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,379 Underlying: Common Stock · 6,421 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2023 Filed May 24, 2023 23:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,421 | $84.23 | $540,840.83 |
DisclosureSEC source: 0001225208-23-006208 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,793.7137 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2023. Read SEC document |
| May 24, 2023 Filed May 24, 2023 23:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,421 | $45.28 | $290,721.69 |
DisclosureSEC source: 0001225208-23-006208 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 220,214.7137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2023. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 9,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005919 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,725 Underlying: Common Stock · 9,725 shares Expires not disclosed F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 65,700 | $0.00 Strike: $88.78 | $0.00 |
DisclosureSEC source: 0001225208-23-005919 · doc4.xml · derivative · entry 3 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,700 Underlying: Common Stock · 65,700 shares Expires 2030-05-10 F3 · derivative.exercise_date: These options were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 7,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005919 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · Global President TAVR & Surg 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,793.7137 F1 · shares: These restricted stock units were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. F2 · balance_after: Reflects shares transferred to the reporting person's ex-spouse pursuant to a divorce judgement. The securities owned by the ex-spouse are not beneficially owned by the reporting person. Read SEC document |
| May 08, 2023 Filed May 9, 2023 23:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,472 | $88.74 | $130,625.28 |
DisclosureSEC source: 0001225208-23-005620 · doc4.xml · nonDerivative · entry 3 Wood Larry L · CIK 0001440660 · CVP & Grp President TAVR & SSH 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,310.7137 Read SEC document |
| May 07, 2023 Filed May 9, 2023 23:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 5,415 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005620 · doc4.xml · derivative · entry 5 Wood Larry L · CIK 0001440660 · CVP & Grp President TAVR & SSH 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,485 Underlying: Common Stock · 5,415 shares Expires 2027-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 07, 2023 Filed May 9, 2023 23:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 2,583 | $88.74 | $229,215.42 |
DisclosureSEC source: 0001225208-23-005620 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP & Grp President TAVR & SSH 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,782.7137 Read SEC document |
| May 07, 2023 Filed May 9, 2023 23:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,415 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005620 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP & Grp President TAVR & SSH 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,365.7137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 04, 2023 Filed May 5, 2023 01:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 396 | $88.10 | $34,887.60 |
DisclosureSEC source: 0001225208-23-005435 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP & Grp President TAVR & SSH 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,950.7137 Read SEC document |
| May 03, 2023 Filed May 5, 2023 01:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 383 | $87.81 | $33,631.23 |
DisclosureSEC source: 0001225208-23-005435 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP & Grp President TAVR & SSH 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,346.7137 Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 23:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 3,235 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002276 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP & Grp President TAVR & SSH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,466.8049 F1 · shares: These restricted stock units were granted on February 16, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| December 13, 2022 Filed Dec 13, 2022 22:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,236 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-22-012623 · doc4.xml · derivative · entry 5 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,236 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2022 Filed Dec 13, 2022 22:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,936 | $76.96 | $533,771.67 |
DisclosureSEC source: 0001225208-22-012623 · doc4.xml · nonDerivative · entry 3 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,231.8049 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $76.43 to $77.40. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 13, 2022 Filed Dec 13, 2022 22:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 300 | $77.48 | $23,244.99 |
DisclosureSEC source: 0001225208-22-012623 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,167.8049 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $77.43 to $77.55. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 13, 2022 Filed Dec 13, 2022 22:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,236 | $36.75 | $265,923.00 |
DisclosureSEC source: 0001225208-22-012623 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,467.8049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2021. Read SEC document |
| November 08, 2022 Filed Nov 8, 2022 23:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,242 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-22-011465 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,236 Underlying: Common Stock · 7,242 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2022 Filed Nov 8, 2022 23:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,242 | $68.50 | $496,064.69 |
DisclosureSEC source: 0001225208-22-011465 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,231.8049 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $68.195 to $68.595. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 08, 2022 Filed Nov 8, 2022 23:01 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,242 | $36.75 | $266,143.50 |
DisclosureSEC source: 0001225208-22-011465 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,473.8049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2021. Read SEC document |
| October 11, 2022 Filed Oct 11, 2022 22:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,242 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-22-010943 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,478 Underlying: Common Stock · 7,242 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2022 Filed Oct 11, 2022 22:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,242 | $82.12 | $594,713.04 |
DisclosureSEC source: 0001225208-22-010943 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,231.8049 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2021. Read SEC document |
| October 11, 2022 Filed Oct 11, 2022 22:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,242 | $36.75 | $266,143.50 |
DisclosureSEC source: 0001225208-22-010943 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,473.8049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2021. Read SEC document |
| September 06, 2022 Filed Sep 6, 2022 22:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,242 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-22-010085 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,720 Underlying: Common Stock · 7,242 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2022 Filed Sep 6, 2022 22:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,242 | $89.00 | $644,538.00 |
DisclosureSEC source: 0001225208-22-010085 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,231.8049 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2021. Read SEC document |
| September 06, 2022 Filed Sep 6, 2022 22:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,242 | $36.75 | $266,143.50 |
DisclosureSEC source: 0001225208-22-010085 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,473.8049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2021. Read SEC document |
| August 09, 2022 Filed Aug 9, 2022 22:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,242 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-22-009403 · doc4.xml · derivative · entry 5 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,962 Underlying: Common Stock · 7,242 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2022 Filed Aug 9, 2022 22:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,324 | $104.59 | $556,856.86 |
DisclosureSEC source: 0001225208-22-009403 · doc4.xml · nonDerivative · entry 3 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,231.8049 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $104.01 to $104.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 09, 2022 Filed Aug 9, 2022 22:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,918 | $105.03 | $201,447.16 |
DisclosureSEC source: 0001225208-22-009403 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,555.8049 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $105.01 to $105.22. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 09, 2022 Filed Aug 9, 2022 22:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,242 | $36.75 | $266,143.50 |
DisclosureSEC source: 0001225208-22-009403 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,473.8049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2021. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 00:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,242 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-22-008534 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,204 Underlying: Common Stock · 7,242 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 00:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,242 | $95.90 | $694,486.07 |
DisclosureSEC source: 0001225208-22-008534 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,231.8049 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $95.205 to $95.910. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 00:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,242 | $36.75 | $266,143.50 |
DisclosureSEC source: 0001225208-22-008534 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,473.8049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2021. Read SEC document |
| June 01, 2022 Filed Jun 1, 2022 22:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,242 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-22-007557 · doc4.xml · derivative · entry 5 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,446 Underlying: Common Stock · 7,242 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2022 Filed Jun 1, 2022 22:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,479 | $100.19 | $448,737.57 |
DisclosureSEC source: 0001225208-22-007557 · doc4.xml · nonDerivative · entry 3 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,199.0338 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $99.76 to $100.75. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2022 Filed Jun 1, 2022 22:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,763 | $101.09 | $279,315.26 |
DisclosureSEC source: 0001225208-22-007557 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,678.0338 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $100.78 to $101.33. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2022 Filed Jun 1, 2022 22:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,242 | $36.75 | $266,143.50 |
DisclosureSEC source: 0001225208-22-007557 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,441.0338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2021. F2 · balance_after: Represents shares transferred to the reporting person's ex-spouse pursuant to a divorce judgement. The securities owned by the ex-spouse are not beneficially owned by the reporting person. Read SEC document |
| May 17, 2022 Filed May 18, 2022 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,816 | $95.93 | $174,208.88 |
DisclosureSEC source: 0001225208-22-007139 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,253.0338 Read SEC document |
| May 10, 2022 Filed May 11, 2022 00:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,242 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-22-006817 · doc4.xml · derivative · entry 9 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,688 Underlying: Common Stock · 7,242 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.